drugset / Trial / NCT00741169
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to assess the interactions seen when somebody doses with TMC435350 and Rifampin (commercial form of antibiotic).
Timeline
- Start
- 2008-06
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifampin | Small molecule | 600 mg | Oral |
| Subject | Simeprevir | Small molecule | 200 mg | Oral |